DCAL
Dishman Carbogen Amcis Limited (DCAL) Stock Analysis
Dishman Carbogen Amcis Limited is an Indian contract research and manufacturing organisation for pharma. It produces APIs and intermediates for global innovators from facilities in India and Europe. CDMO demand and complex chemistry capabilities support its business. The company is listed on Indian stock exchanges and operates from India.
Healthcare › Biotechnology
₹172.90
+10.39% 1W | -28.80% 52W
Market Cap
2.7k CR
P/E Ratio
167.9
52W High
₹274.3
52W Low
₹128.5
Div. Yield
0%
Beta
0.7
50 DMA
₹157.5
200 DMA
₹174.2
Profit Margin
0.6%
Inst. Own.
2.7%
🚀 BREAKOUT
🚀 BREAKOUT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 723 | 587 | 651 | 655 | 524 | 789 | 682 | 716 | 708 | 653 | 720 | 851 | 678 |
| YoY Sales growth | +34% | -4% | +2% | +6% | -28% | +35% | +5% | +9% | +35% | -17% | +5% | +19% | -4% |
| Expenses | 602 | 526 | 610 | 592 | 495 | 642 | 542 | 564 | 567 | 504 | 607 | 688 | 618 |
| Operating Profit | 122 | 61 | 41 | 63 | 29 | 147 | 140 | 153 | 141 | 149 | 113 | 163 | 60 |
| OPM % | 17% | 10% | 6% | 10% | 6% | 19% | 21% | 21% | 20% | 23% | 16% | 19% | 9% |
| Other Income | 7 | 5 | 6 | 4 | -4 | 4 | 8 | -4 | 22 | 8 | 7 | 15 | 16 |
| Interest | 28 | 27 | 33 | 31 | 32 | 37 | 49 | 42 | 43 | 42 | 46 | 43 | 37 |
| Depreciation | 70 | 75 | 80 | 85 | 71 | 72 | 72 | 79 | 81 | 84 | 84 | 89 | 91 |
| Profit before tax | 29 | -36 | -66 | -49 | -78 | 42 | 27 | 28 | 39 | 31 | -10 | 46 | -51 |
| Tax % | 42% | 13% | -10% | 42% | 0% | 21% | 83% | -56% | 39% | -114% | 24% | 53% | 13% |
| Net Profit | 17 | -41 | -60 | -70 | -78 | 33 | 5 | 43 | 23 | 65 | -13 | 22 | -58 |
| EPS in Rs | 1.08 | -2.61 | -3.80 | -4.46 | -4.95 | 2.11 | 0.30 | 2.75 | 1.49 | 4.16 | -0.83 | 1.39 | -3.69 |
| Metric | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,031 | 1,714 | 1,695 | 2,059 | 2,044 | 1,912 | 2,141 | 2,413 | 2,616 | 2,712 | 2,932 | 2,901 |
| Sales growth | -1% | +21% | -1% | -6% | +12% | +13% | +8% | +4% | +8% | +0% | ||
| Expenses | 830 | 1,261 | 1,249 | 1,507 | 1,540 | 1,638 | 1,809 | 2,081 | 2,329 | 2,243 | 2,366 | 2,416 |
| Operating Profit | 201 | 452 | 445 | 552 | 503 | 274 | 331 | 332 | 286 | 469 | 566 | 485 |
| OPM % | 20% | 26% | 26% | 27% | 25% | 14% | 15% | 14% | 11% | 17% | 19% | 17% |
| Other Income | 14 | 26 | 46 | 54 | 39 | 16 | 29 | -20 | 22 | 4 | 52 | 47 |
| Interest | 56 | 49 | 49 | 57 | 62 | 48 | 57 | 86 | 120 | 159 | 174 | 169 |
| Depreciation | 69 | 214 | 211 | 240 | 283 | 308 | 308 | 281 | 311 | 294 | 339 | 348 |
| Profit before tax | 91 | 216 | 231 | 309 | 197 | -65 | -4 | -55 | -122 | 19 | 105 | 15 |
| Tax % | 12% | 33% | 33% | 32% | 20% | 154% | -524% | -45% | 26% | 83% | 7% | |
| Net Profit | 80 | 145 | 155 | 210 | 159 | -165 | 18 | -30 | -153 | 3 | 97 | 16 |
| EPS in Rs | 9.58 | 13.03 | 10.10 | -10.53 | 1.15 | -1.90 | -9.79 | 0.21 | 6.22 | 1.03 | ||
| Dividend Payout % | 0% | 0% | 0% | 2% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 7.0% | 9.0% | – |
| Profit CAGR | 140.0% | 21.0% | – |
Shareholding Pattern
Promoters59.32%
FIIs8.07%
DIIs1.37%
Public31.23%
Promoters59.32%
FIIs7.66%
DIIs1.27%
Public31.75%
Promoters59.32%
FIIs7.45%
DIIs1.63%
Public31.60%
Promoters59.32%
FIIs6.86%
DIIs2.06%
Public31.76%
Promoters59.32%
FIIs6.96%
DIIs1.65%
Public32.05%
Promoters59.32%
FIIs9.34%
DIIs2.55%
Public28.79%
Promoters59.32%
FIIs8.70%
DIIs2.36%
Public29.63%
Promoters59.32%
FIIs9.49%
DIIs1.26%
Public29.94%
Promoters59.32%
FIIs7.45%
DIIs1.63%
Public31.60%
Promoters59.32%
FIIs6.96%
DIIs1.65%
Public32.05%
DCAL
Holdings Analysis
Key strengths & risk signals
54
Overall
39
Fundamental
70
Technical
Risks (3)
Cannot calculate PEG - insufficient growth data.
POOR YEAR! Stock declined 28.8% in the last year.
LOWER HALF! Trading at 30.5% of 52W range - weakness visible.
Strengths (3)
BREAKOUT! Stock has broken above resistance levels with momentum.
LOW VOLATILITY! Beta of 0.70 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 11 up days, 18 down days. Avg volume on up days: 287,201 vs down days: 201,864. Ratio: 1.42x
Fundamental & Technical Analysis
54Overall
39Fundamental
70Technical
Fundamental Breakdown
Growth Quality
10/30
Revenue CAGR: 7.5% (MODERATE, 8/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! 0.6% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
8/10
LOW DEBT! D/E of 0.41 - strong balance sheet.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 28.65% public ownership - balanced ownership structure.
Stability Index
2/10
CAUTION! Company made loss in last quarter. Be careful.
Technical Breakdown
Moving Averages
5/10
BEARISH TREND! 50-day average (157.5) is below 200-day average (174.2) - negative signal.
Price Position
6/10
MIXED POSITION! Current price (172.9) above 50-day but below 200-day.
Trend Pattern
20/20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance
1/10
POOR YEAR! Stock declined 28.8% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 11 up days, 18 down days. Avg volume on up days: 287,201 vs down days: 201,864. Ratio: 1.42x
RSI
3/5
BULLISH! RSI at 61.2 - positive momentum.
52W Range
2/5
LOWER HALF! Trading at 30.5% of 52W range - weakness visible.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - 10.4% (1 week), 13.0% (1 month), -9.3% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.70 - stable stock, less market risk.
DCAL
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-05-25 | Concall PDF | |
| Q3FY262026-02-10 | Concall PDF | |
| Q2FY262025-11-11 | Concall PDF |
Peer Comparison
Healthcare · Biotechnology · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DCAL | ₹172.90 | 167.9 | 0.6% | 7.5% | – | -28.8% | 54 | BREAKOUT | -347.4% | -366.8% | -4.3% | -20.4% |
| PANACEABIO | ₹354.40 | – | -1.1% | 10.1% | – | -12.6% | 47 | CONSOLIDATING DOWN | -42.5% | +360.0% | +19.7% | +19.7% |
| 3BBLACKBIO | ₹1,341.50 | 19.7 | 36.3% | 31.9% | 32.2% | +17.4% | 72 | BREAKDOWN | -24.6% | -1.0% | +50.9% | -5.4% |
| ZOTA | ₹1,297.10 | – | -16.6% | 56.7% | – | -14.0% | 56 | BREAKDOWN | +204.9% | +207.0% | +67.6% | +6.4% |
| HALEOSLABS | ₹1,590.40 | 30.4 | 3.9% | 5.0% | 5.0% | +10.8% | 66 | BREAKOUT | -71.1% | -32.3% | +12.3% | +25.3% |
| LYKALABS | ₹84.60 | – | -6.6% | 12.1% | – | -8.5% | 57 | CONSOLIDATING DOWN | -138.2% | -38.1% | +20.4% | +4.5% |
| SUPRIYA | ₹632.10 | 28.7 | 22.7% | 21.2% | 32.5% | -18.9% | 67 | BREAKDOWN | -42.1% | +21.7% | +3.3% | +8.8% |
| BLUEJET | ₹539.40 | 33.6 | 26.0% | 9.4% | 15.7% | -7.8% | 71 | BOUNCE FROM SUPPORT | – | +30.9% | – | +28.2% |
Data from TradeAlone · Updated daily
DCAL News
Dishman Carbogen Amcis Limited (dcal) Q1fy27: Net Revenue Dips, CDMO Segment Struggles2026-08-17Dishman Carbogen Amcis Limited DCAL: Carbogen AMCIS AG Commissions 1,200 Kwp Solar Power Plant2026-06-29Dishman Carbogen Amcis Limited (dcal) Q4fy26: Revenue Surges 18.9%, PAT Up 446%2026-05-20Dcal Subsidiary Achieves Successful Gmp Inspection in China2026-05-05
